Lead Sponsor

89bio, Inc.

Age

22 - No limit years

Sex

ALL

Healthy Volunteers

No

•Age ≥22 years
•Willing to enter a medication/lifestyle stabilization period during the screening period, which means maintaining those stable medication, eating, and exercise habits for the duration of the study
•Subjects should be on stable background Lipid Modifying Therapy (LMT) to manage ASCVD for a minimum of 4 weeks prior to first qualifying TG

•Positive for hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV)
•Uncontrolled or newly diagnosed (≤3 months since diagnosis) Type 2 diabetes mellitus as determined by the Principal Investigator. Subjects must have HbA1c level ≤9.5% at Screening. Medications for glucose management must be stable for at least 4 weeks prior to Screening
•Type 1 diabetes mellitus
•A history of symptomatic gallstone disease, gallstone pancreatitis (unless treated with cholecystectomy), or any other ongoing symptomatic biliary disease
•Acute pancreatitis within 6 months prior to Screening
•Subjects with chronic pancreatitis
•Known or suspected familial chylomicronemia syndrome (FCS) (Type 1 hyperlipoproteinemia)